Charles River Laboratories International Financial Statements
NYSE: CRLHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Charles River Laboratories International revenue and earnings
In fiscal 2025, Charles River Laboratories International generated $4.02 billion in revenue, down 0.9% from fiscal 2024, its first annual decline since 2024. Charles River Laboratories International reported a net loss of $144.3 million, compared with net income of $22.2 million a year earlier. Operating margin was 0.6%.
Diluted earnings per share came in at -$2.91, down from $0.20. Over the last 5 fiscal years, CRL's revenue has grown at a 6.5% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Charles River Laboratories International income statement (annual)
| Fiscal year (USD) | FY 20252025-12-27 | FY 20242024-12-28 | FY 20232023-12-30 | FY 20222022-12-31 | FY 20212021-12-25 | FY 20202020-12-26 | FY 20192019-12-28 | FY 20182018-12-29 | FY 20172017-12-30 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.02B | 4.05B | 4.13B | 3.98B | 3.54B | 2.92B | 2.62B | 2.27B | 1.86B | 1.68B |
| Revenue growth (YoY) | -0.85% | -1.92% | +3.86% | +12.31% | +21.08% | +11.55% | +15.67% | +21.99% | +10.48% | +23.34% |
| Cost of Revenue | — | — | — | — | — | — | — | — | 289.67M | 277.03M |
| Gross Profit | — | — | — | — | — | — | — | — | 1.57B | 1.40B |
| Operating Expenses | — | — | — | — | — | — | — | — | 1.28B | 1.17B |
| Selling, General & Admin | 743.07M | 751.00M | 747.86M | 665.10M | 619.92M | 528.93M | 517.62M | 443.85M | 371.27M | 364.71M |
| Operating Income | 25.16M | 227.35M | 617.26M | 650.98M | 589.86M | 432.73M | 351.15M | 331.38M | 288.28M | 237.55M |
| Interest Expense | 107.03M | 126.29M | 136.71M | 59.29M | 73.91M | 86.43M | 60.88M | 63.77M | 29.78M | 27.71M |
| Other Income (Expense) | -22.58M | -16.52M | 95.54M | 30.52M | -35.89M | 99.98M | 12.29M | 13.26M | 37.76M | 11.76M |
| Pretax Income | -99.50M | 93.11M | 581.28M | 622.99M | 480.71M | 447.11M | 304.08M | 281.68M | 296.95M | 222.92M |
| Income Tax | 42.66M | 67.82M | 100.91M | 130.38M | 81.87M | 81.81M | 50.02M | 54.46M | 171.37M | 66.83M |
| Net Income | -144.34M | 22.20M | 474.62M | 486.23M | 390.98M | 364.30M | 252.02M | 226.37M | 123.36M | 154.76M |
| Net Income growth (YoY) | -750.08% | -95.32% | -2.39% | +24.36% | +7.32% | +44.55% | +11.33% | +83.51% | -20.30% | +3.65% |
| EPS (Basic) | -2.91 | 0.20 | 9.27 | 9.57 | 7.77 | 7.35 | 5.17 | 4.72 | 2.60 | 3.29 |
| EPS (Diluted) | -2.91 | 0.20 | 9.22 | 9.48 | 7.60 | 7.20 | 5.07 | 4.62 | 2.54 | 3.23 |
| Shares Outstanding (Basic) | 49.56M | 51.38M | 51.23M | 50.81M | 50.29M | 49.55M | 48.73M | 47.95M | 47.48M | 47.01M |
| Shares Outstanding (Diluted) | 49.56M | 51.63M | 51.45M | 51.30M | 51.42M | 50.61M | 49.69M | 49.02M | 48.56M | 47.96M |
| EBITDA | 428.47M | 589.09M | 931.38M | 954.85M | 855.40M | 667.65M | 549.25M | 493.16M | 419.44M | 364.21M |
| Gross Margin | — | — | — | — | — | — | — | — | 84.41% | 83.52% |
| Operating Margin | 63.00% | 5.61% | 14.95% | 16.37% | 16.66% | 14.80% | 13.40% | 14.62% | 15.52% | 14.13% |
| Net Margin | -3.59% | 55.00% | 11.49% | 12.23% | 11.04% | 12.46% | 9.61% | 9.99% | 6.64% | 9.20% |
This table shows 10 annual periods of Charles River Laboratories International's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CRL's reporting calendar. What is a income statement?